Meng Tiantian, Ding Jingyi, Shen Shujie, Xu Yingzhi, Wang Peng, Song Xinbin, Li Yixiang, Li Shangjin, Xu Minjie, Tian Ziyu, He Qingyong
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100032, China.
Department of Rehabilitation, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100071, China.
Heliyon. 2023 Aug 19;9(9):e19163. doi: 10.1016/j.heliyon.2023.e19163. eCollection 2023 Sep.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide and become a major global public health concern. Although novel investigational COVID-19 antiviral candidates such as the Pfizer agent PAXLOVID™, molnupiravir, baricitinib, remdesivir, and favipiravir are currently used to treat patients with COVID-19, there is still a critical need for the development of additional treatments, as the recommended therapeutic options are frequently ineffective against SARS-CoV-2. The efficacy and safety of vaccines remain uncertain, particularly with the emergence of several variants. All 10 versions of the National Health Commission's diagnosis and treatment guidelines for COVID-19 recommend using traditional Chinese medicine. Xuanfei Baidu Decoction (XFBD) is one of the "three Chinese medicines and three Chinese prescriptions" recommended for COVID-19. This review summarizes the clinical evidence and potential mechanisms of action of XFBD for COVID-19 treatment. With XFBD, patients with COVID-19 experience improved clinical symptoms, shorter hospital stay, prevention of the progression of their symptoms from mild to moderate and severe symptoms, and reduced mortality in critically ill patients. The mechanisms of action may be associated with its direct antiviral, anti-inflammatory, immunomodulatory, antioxidative, and antimicrobial properties. High-quality clinical and experimental studies are needed to further explore the clinical efficacy and underlying mechanisms of XFBD in COVID-19 treatment.
2019冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，已在全球范围内传播，成为全球主要的公共卫生问题。尽管目前使用新型的COVID-19抗病毒候选药物，如辉瑞公司的PAXLOVID™、莫努匹拉韦、巴瑞替尼、瑞德西韦和法匹拉韦来治疗COVID-19患者，但由于推荐的治疗方案对SARS-CoV-2常常无效，因此仍然迫切需要开发更多的治疗方法。疫苗的有效性和安全性仍然不确定，尤其是随着几种变体的出现。国家卫生健康委的所有10版COVID-19诊断和治疗指南均推荐使用中药。宣肺败毒汤（XFBD）是推荐用于COVID-19的“三药三方”之一。本综述总结了宣肺败毒汤治疗COVID-19的临床证据和潜在作用机制。使用宣肺败毒汤，COVID-19患者的临床症状得到改善，住院时间缩短，可预防症状从轻症进展为中重症，并降低重症患者的死亡率。其作用机制可能与其直接抗病毒、抗炎、免疫调节、抗氧化和抗菌特性有关。需要高质量的临床和实验研究来进一步探索宣肺败毒汤在COVID-19治疗中的临床疗效和潜在机制。
